Welcome text
You have been approached to complete this survey as an expert in your professional field of viral hepatitis care, and/or as part of your involvement in a national or regional level organisation that represents clinicians and/or public health professionals. It is from this representative position that we would like you to respond to the survey. We are interested in the general or routine viral hepatitis related screening and clinical management practices in your country.

This survey has been sent to experts in seven different countries in the EU. We recognise that practices will differ between the seven countries and have tried to reflect this diversity in the structure and answering options. Although there may be aspects of the survey that are not applicable to the situation in your country, the structure of the survey will enable you to reflect that in your answers.

The survey will take approximately 15 minutes. It is possible to stop and complete the survey at a later time.

Please be assured that your responses will be kept anonymous.

Section 1: Respondent profile
These questions relate to your involvement in a national or regional level organisation that represents clinicians and/or public health professionals and/or patients.

1. What is the name of your organisation? ..................

2. What type of organisation is it?
   - NGO
   - National Government
   - Regional Government
   - Clinical Association
   - Professional Organisation
   - University
   - Patient association
   - Other (please specify): ..........

3. What is your Job Role/Job Title: ...........

4. Do you also have clinical responsibilities and are directly involved in the care of patients?
   - Yes
   - No [skip to section 2]

5. [If YES to have clinical responsibilities and to be directly involved in the care of patients]
   What type of medical facility do you work in?
   - GP practice
   - Public health service/health protection unit
   - Clinic (outside a hospital)
   - General hospital
   - University/Teaching hospital
6. [If YES to have clinical responsibilities and to be directly involved in the care of patients] What is your medical specialism/clinical role?
   - General Practitioner
   - Infectious Disease specialist
   - Gastroenterologist/Hepatologist
   - Gynaecologist/Obstetrician
   - Other (please specify): ...........

7. [If YES to have clinical responsibilities and to be directly involved in the care of patients] How often do you see patients with a chronic hepatitis B or hepatitis C infection?
   - Never
   - A few patients per year (1-10)
   - On a monthly basis
   - On a weekly basis

Section 2: Referral to secondary care and disease-related advice and guidance (counselling):
8. In your experience, how common is it for professionals in your speciality to receive their hepatitis B/C patients from the following settings/specialities. If there are other settings/specialities, please give details.

<table>
<thead>
<tr>
<th>Setting/Speciality</th>
<th>Very common</th>
<th>Variable or not routinely</th>
<th>Rarely or never</th>
<th>Unsure</th>
</tr>
</thead>
<tbody>
<tr>
<td>General Practitioner</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Public health services/health protection units</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Sexual Health Services/Genito-urinary medicine clinics</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Midwives/Obstetrician/Gynaecologist</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asylum seeker service</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Infectious Disease specialists</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Referral from an outreach screening programme</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Referral from centres testing injecting drug users</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

9. If there are other settings/specialities, please give details.

10. Who has the **main responsibility** for providing disease-related advice and guidance (counselling) to patients following a positive diagnosis for viral hepatitis in your country?
    - General Practitioners
    - Public health services/health protection units
    - Infectious disease specialists (not in public health services/health protection units)
    - Specialists (e.g. Gastroenterologists/Hepatologists)
    - Other (please specify)
Section 3: Content of disease-related advice and guidance (counselling):

11. How common is it for professionals in your speciality to include the following topics in the consultation with a hepatitis B or C patient:

<table>
<thead>
<tr>
<th>Consultation topics</th>
<th>Very common</th>
<th>Variable or not routinely</th>
<th>Rarely or never</th>
<th>Unsure</th>
</tr>
</thead>
<tbody>
<tr>
<td>General information about the disease</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Hygiene measures to prevent transmission to others</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Contact tracing</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other tests required</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Treatment options, benefits and side effects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>The importance of a healthy lifestyle, especially the damaging role of alcohol consumption</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Mental health promotion and staying positive</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patient organisations / support groups</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Section 4: Screening/testing positive patients for other hepatitis viruses:

12. Are hepatitis B positive patients screened/tested for hepatitis C?
   - No
   - Yes – all patients
   - Yes – a selection of patients (please specify which)
   - Unsure

13. Are hepatitis C positive patients screened/tested for hepatitis B?
   - No
   - Yes – all patients
   - Yes – a selection of patients (please specify which)
   - Unsure

14. [If YES to screening/testing of hepatitis B/C positive patients for other viruses]
   Who has the main responsibility for screening/testing of hepatitis B or hepatitis C positive patients for other hepatitis viruses?
   - General Practitioners
   - Public health services/health protection units
   - Hospitals/clinics
   - Sexual Health Services
   - Other (please specify)

15. Are hepatitis C positive patients who are found to be hepatitis B negative vaccinated against hepatitis B?
   - No
   - Yes – all patients
   - Yes – a selection of patients (please specify)
   - Unsure

16. [If YES to hepatitis B vaccination of hepatitis C positive patients found to be hepatitis B negative]
   Who has the main responsibility for vaccination of hepatitis C positive patients found hepatitis B negative?
   - General Practitioners
   - Public health services/health protection units
   - Hospitals/clinics
Section 5: Contact tracing and vaccination:
17. Is hepatitis B screening/testing offered to contacts (household and/or sexual contacts) of hepatitis B positive patients?
   - No
   - Yes — all contacts
   - Yes — a selection of contacts (please specify)
   - Unsure

18. Are hepatitis B negative contacts (household and/or sexual contacts) of hepatitis B positive patients vaccinated?
   - No
   - Yes — all hepatitis B negative contacts
   - Yes — a selection of hepatitis B negative contacts (please specify)
   - Unsure

19. [If YES to vaccination offered to hepatitis B negative contacts of hepatitis B positive patients] Who has responsibility for vaccination of contacts?
   - General Practitioners
   - Public health services/health protection units
   - Sexual Health Services
   - Hospitals/clinics
   - Other (please specify)

20. Is hepatitis C screening/testing offered to contacts (household and/or sexual contacts) of hepatitis C positive patients?
   - No
   - Yes — all contacts
   - Yes — a selection of contacts (please specify)
   - Unsure

21. [If YES to screening/testing offered to contacts of hepatitis B/C positive patients] Who has the main responsibility for the screening/testing of contacts for hepatitis B and C?
   - General Practitioners
   - Public health services/health protection units
   - Sexual Health Services
   - Hospitals/clinics
   - Other (please specify)

Section 6: The role of the GP:

22. How common is it that the following patients would be referred back to their GP from specialist care?

<table>
<thead>
<tr>
<th>Patient groups</th>
<th>Very common</th>
<th>Variable or not routinely</th>
<th>Rarely or never</th>
<th>Unsure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Those who do not qualify for treatment after the initial evaluation</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Those undergoing antiviral treatment</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Those who have sustained virological response</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
23. How common is it that a **GP** would be involved in monitoring the following indicators in a patient **undergoing antiviral treatment**?

<table>
<thead>
<tr>
<th></th>
<th>Very common</th>
<th>Variable or not routinely</th>
<th>Rarely or never</th>
<th>Unsure</th>
</tr>
</thead>
<tbody>
<tr>
<td>ALT levels</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Viral load</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Side effects</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Section 7: Diagnostics**

24. How common is it for the following diagnostics to be used in the initial evaluation of a hepatitis B or C positive patient?

<table>
<thead>
<tr>
<th>Diagnostics</th>
<th>Very common</th>
<th>Variable or not routinely</th>
<th>Rarely or never</th>
<th>Unsure</th>
</tr>
</thead>
<tbody>
<tr>
<td>HBeAg and/or anti-HBe (for hepatitis B only)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>ALT</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Other biochemical markers (AST, GGT, serum albumin, etc)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Quantitative viral load (hepatitis B DNA or hepatitis C RNA)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Genotype</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ultrasound</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Liver biopsy</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Transient elastography (e.g. fibroscan)</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

**Section 8: Treatment options:**

25. Are there **limitations** on the use of the following antiviral drugs for **hepatitis B**?

<table>
<thead>
<tr>
<th>HBV drugs</th>
<th>No limitations</th>
<th>Yes – some restrictions</th>
<th>Yes – totally limited / cannot be prescribed</th>
<th>Unsure</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Pegylated) Interferon alpha</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lamivudine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Telbivudine</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Adefovir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Entecavir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Tenofovir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

26. [If YES to some restriction on the use of Interferon alpha]
   What are the **restrictions** for **Interferon alpha**?
   - □ Can only be prescribed if resistance to another drug has developed
   - □ Can only be prescribed for a limited duration
27. [If YES to some restriction on the use of Lamivudine]
What are the restrictions for Lamivudine?
☐ Can only be prescribed if resistance to another drug has developed
☐ Can only be prescribed for a limited duration
☐ Can only be prescribed by selected hospitals (e.g. tertiary centers)
☐ Can only be prescribed in selected geographic areas
☐ Other restrictions, please give details:

28. [If YES to some restriction on the use of Telbivudine]
What are the restrictions for Telbivudine?
☐ Can only be prescribed if resistance to another drug has developed
☐ Can only be prescribed for a limited duration
☐ Can only be prescribed by selected hospitals (e.g. tertiary centers)
☐ Can only be prescribed in selected geographic areas
☐ Other restrictions, please give details:

29. [If YES to some restriction on the use of Adefovir]
What are the restrictions for Adefovir?
☐ Can only be prescribed if resistance to another drug has developed
☐ Can only be prescribed for a limited duration
☐ Can only be prescribed by selected hospitals (e.g. tertiary centers)
☐ Can only be prescribed in selected geographic areas
☐ Other restrictions, please give details:

30. [If YES to some restriction on the use of Entecavir]
What are the restrictions for Entecavir?
☐ Can only be prescribed if resistance to another drug has developed
☐ Can only be prescribed for a limited duration
☐ Can only be prescribed by selected hospitals (e.g. tertiary centers)
☐ Can only be prescribed in selected geographic areas
☐ Other restrictions, please give details:

31. [If YES to some restriction on the use of Tenofovir]
What are the restrictions for Tenofovir?
☐ Can only be prescribed if resistance to another drug has developed
☐ Can only be prescribed for a limited duration
☐ Can only be prescribed by selected hospitals (e.g. tertiary centers)
☐ Can only be prescribed in selected geographic areas
☐ Other restrictions, please give details:
32. Are there **limitations** on the use of the following antiviral drugs for **hepatitis C**?

<table>
<thead>
<tr>
<th>HCV drugs</th>
<th>No limitations</th>
<th>Yes – some restrictions</th>
<th>Yes – totally limited / cannot be prescribed</th>
<th>Unsure</th>
</tr>
</thead>
<tbody>
<tr>
<td>(Pegylated) Interferon alpha</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Ribavirin</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Telaprevir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Boceprevir</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

33. [If YES to some restriction on the use of Interferon alpha]

What are the **restrictions** for **Interferon alpha**?

- □ Can only be prescribed if resistance to another drug has developed
- □ Can only be prescribed for a limited duration
- □ Can only be prescribed by selected hospitals (e.g. tertiary centers)
- □ Can only be prescribed in selected geographic areas
- □ Other restrictions, please give details:

34. [If YES to some restriction on the use of Ribavirin]

What are the **restrictions** for **Ribavirin**?

- □ Can only be prescribed if resistance to another drug has developed
- □ Can only be prescribed for a limited duration
- □ Can only be prescribed by selected hospitals (e.g. tertiary centers)
- □ Can only be prescribed in selected geographic areas
- □ Other restrictions, please give details:

35. [If YES to some restriction on the use of Telaprevir]

What are the **restrictions** for **Telaprevir**?

- □ Can only be prescribed if resistance to another drug has developed
- □ Can only be prescribed for a limited duration
- □ Can only be prescribed by selected hospitals (e.g. tertiary centers)
- □ Can only be prescribed in selected geographic areas
- □ Other restrictions, please give details:

36. [If YES to some restriction on the use of Boceprevir]

What are the **restrictions** for **Boceprevir**?

- □ Can only be prescribed if resistance to another drug has developed
- □ Can only be prescribed for a limited duration
- □ Can only be prescribed by selected hospitals (e.g. tertiary centers)
- □ Can only be prescribed in selected geographic areas
- □ Other restrictions, please give details:
37. Is **treatment** restricted for any of the following patient groups?

<table>
<thead>
<tr>
<th>Patient groups</th>
<th>No restrictions</th>
<th>Some restrictions</th>
<th>Significant restrictions</th>
<th>Yes completely restricted</th>
<th>Unsure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Undocumented migrants without health care coverage or health insurance</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients without health care coverage or health insurance (not i)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Asylum seekers (still in application procedure)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Injecting drug users (current users)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients abusing alcohol (current abusers)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

Section 9: Professional practice and training:

38. How common is it for professionals in your speciality to have the following available for patients:

<table>
<thead>
<tr>
<th></th>
<th>Very common</th>
<th>Variable or not routinely</th>
<th>Rarely or never</th>
<th>Unsure</th>
</tr>
</thead>
<tbody>
<tr>
<td>Materials about viral hepatitis in the national language</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Materials about viral hepatitis in other languages</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Interpreter services via a telephone</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Face to face interpreter services</td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

39. Is training available for professionals in your speciality to improve their knowledge and skills in the clinical management of viral hepatitis?
   - Yes (please give details)
   - No
   - Unsure

Make a comment on your choice here:

40. Is there a list of nationally certified centres/centres of excellence for the management and treatment of chronic hepatitis B and C?
   - Yes (please give details)
   - No
   - Unsure

Make a comment on your choice here:
**Section 9: Professional practice and training for hepatitis B:**

41. Are there any official national guidelines about Hepatitis B screening and patient management in place in your country? If yes, please give name and publisher:
   - General Hepatitis B guidelines: ..................
   - Specific guidelines for specialists: .................
   - Other hepatitis B guidelines: ..................

42. [If there are official national guidelines about Hepatitis B screening and patient management in your country]
   Does this specific guideline for specialists include information about:
   - Clinical indications and risk factors to prompt a test for hepatitis B
   - Pre-test information and advice for patients
   - Disease-related advice and guidance (counselling) for patients following positive diagnosis
   - Onward referral of chronic viral hepatitis patients to other services
   - Recommendations to tailor services or information for people from a migrant or ethnic minority background
   - Assessment of liver disease
   - Treatment strategies

**Section 9: Professional practice and training for hepatitis B:**

43. Are there any official national guidelines about Hepatitis C screening and patient management in place in your country? If yes, please give name and publisher:
   - General Hepatitis C guidelines: ..................
   - Specific guidelines for specialists: .................
   - Other hepatitis C guidelines: ..................

44. [If there are official national guidelines about Hepatitis C screening and patient management in your country]
   Does this specific guideline for specialists include information about:
   - Clinical indications and risk factors to prompt a test for hepatitis C
   - Pre-test information and advice for patients
   - Disease-related advice and guidance (counselling) for patients following positive diagnosis
   - Onward referral of chronic viral hepatitis patients to other services
   - Recommendations to tailor services or information for people from a migrant or ethnic minority background
   - Assessment of liver disease
   - Treatment strategies

**Section 10: Barrier questions:**

**Uptake of screening among at risk groups**

45. To what extent do you agree with the following statements as explanations of the current low uptake of hepatitis B and C screening among people from a migrant or ethnic minority background in your country.
<table>
<thead>
<tr>
<th>Statements</th>
<th>Strongly disagree</th>
<th>Disagree</th>
<th>Neither agree nor disagree</th>
<th>Agree</th>
<th>Strongly agree</th>
</tr>
</thead>
<tbody>
<tr>
<td>Limited awareness and knowledge about hepatitis B and C in general (including the ways of transmission) and their consequences (e.g. the link to liver cancer)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Subjective feeling of being healthy and hence unlikely to be infected with hepatitis B/C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>First generation migrants from hepatitis B and C endemic countries are not aware that they have a significantly higher risk of being infected with hepatitis B/C</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Limited awareness that screening and subsequent treatment can prevent future complications</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Fear of social stigma and discrimination if found to be hepatitis B/C positive (e.g. fear of losing job)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lack of information about where to go for a test</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Lack of access to free/affordable health care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Language barriers when visiting health services (limited availability of translated materials or interpreter services)</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>

46. If you think there are other explanations, please give details in the box below.

---

**Screening offered by primary health care providers**

47. To what extent do you agree with the following statements as explanations of why migrants are not being screened/tested for hepatitis B/C at the point of first contact with primary health care services/GPs in your country.

<table>
<thead>
<tr>
<th>Statements</th>
<th>Strongly disagree</th>
<th>Disagree</th>
<th>Neither agree nor disagree</th>
<th>Agree</th>
<th>Strongly agree</th>
</tr>
</thead>
<tbody>
<tr>
<td>Health services are unable to identify patients with migration-related risk factors (such as country of birth or ethnic origin) as this data is not routinely collected</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Primary care providers/GPs are not aware that migrants from hepatitis B and C endemic countries have a significantly higher risk and should be offered screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Patients refuse testing despite primary care providers/GPs offering screening</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
Limited awareness among primary health care providers/GPs about the scope of new, improved antiviral treatments that can potentially cure the disease or significantly reduce disease progression

Primary care providers/GPs rarely have translated materials about viral hepatitis or interpreter services available for patients

Hepatitis screening of asymptomatic risk groups is generally not covered under the general health care service/insurance scheme in my country

There is limited guidance available to primary health care professionals/GPs on screening for viral hepatitis among at risk groups

Health care professionals/GPs do not have time to offer screening

48. If you think there are other explanations, please give details in the box below.

Disease-related counselling, onward referral and clinical management of hepatitis B/C patients.

49. To what extent do you agree with the following statements as explanations of why hepatitis B/C cases do not reach specialized health care (e.g. hepatologists) for further investigation and treatment in your country.

<table>
<thead>
<tr>
<th>Statements</th>
<th>Strongly disagree</th>
<th>Disagree</th>
<th>Neither agree nor disagree</th>
<th>Agree</th>
<th>Strongly agree</th>
</tr>
</thead>
<tbody>
<tr>
<td>In antenatal screening programmes the focus is mainly on vaccination of the baby of hepatitis B positive mothers, not on hepatitis care for the women testing positive</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Time constraints affect health care professionals/GPs ability to provide patients with disease-related counselling and referral advice</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Some health care services are not reimbursed for providing disease-related counselling and referral advice to patients</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>Newly diagnosed patients generally do not receive comprehensive counselling on the consequences of the disease, treatment options and referral, and hence do not seek specialist care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
<tr>
<td>There are too few specialists to whom the patients can be referred to for specialized care</td>
<td></td>
<td></td>
<td></td>
<td></td>
<td></td>
</tr>
</tbody>
</table>
The antiviral treatment itself is generally not covered under the general health care service/insurance scheme in my country

Patients are referred to the specialist but refuse further investigation or treatment

There is limited guidance available to primary health care professionals about onward referral, counselling and patient management of hepatitis B/C patients

Although training on viral hepatitis management is available for health care providers, uptake is generally low among professionals.

Patients from a migrant or ethnic minority background face language barriers when visiting health services (limited availability of translated materials or interpreter services)

50. If you think there are other explanations, please give details in the box below.

<table>
<thead>
<tr>
<th>Section 11: Awareness raising/outreach campaigns:</th>
</tr>
</thead>
<tbody>
<tr>
<td>51. Are you aware of any campaigns or outreach programmes that aim to increase awareness of and promote screening for hepatitis B and/or C among migrant or ethnic minority groups in your country?</td>
</tr>
<tr>
<td>o Yes (please give details below)</td>
</tr>
<tr>
<td>o Not in detail/not personally but I know people who are aware of migrant-specific hepatitis screening programmes (please give details below)</td>
</tr>
<tr>
<td>o No – I’m not aware of any</td>
</tr>
<tr>
<td>o No – I know there are none</td>
</tr>
</tbody>
</table>

52. [if Yes or Not in detail: Option to give details for up to 5 campaigns]

<table>
<thead>
<tr>
<th>Name and Job Role of Coordinator</th>
</tr>
</thead>
<tbody>
<tr>
<td>Organisation</td>
</tr>
<tr>
<td>Contact details</td>
</tr>
<tr>
<td>Name of the campaign:</td>
</tr>
<tr>
<td>Nationality/ethnicity of target population(s)</td>
</tr>
<tr>
<td>Setting(s) where target population are contacted (e.g. mosque, church, community centre, shops, online, home etc.)</td>
</tr>
<tr>
<td>Year and duration (e.g. weeks/months/years/ongoing)</td>
</tr>
<tr>
<td>Website</td>
</tr>
</tbody>
</table>
Comments
53. If you have any comments about the survey in general or regarding the screening, counselling, referral and/or treatment of Hepatitis B/C in your country, we would be grateful to learn more and benefit from your experience. Please write any comments in the text box below.

Thank you for completing this survey.